Clinical trials: Diffuse Parenchymal Lung Diseases
Pulmonary Fibrosis of Any Cause, Primary Supporters/Caretakers of Patients With Pulmonary Fibrosis
Pulmonary Fibrosis Contact Registry
As the name states, contact registries securely store contact information from groups of reasonably well-characterized patients (or primary supporters/caregivers) who are interested in being informed about ongoing or future…
- Trial name
- NCT01935726
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Non-small Cell Lung Cancer Stage III
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Patients with stage III non-small-cell lung cancer initially evaluated as unresectable are selected for the program, who are remained unresectable after 2-4 cycles of conversion chemotherapy combined with immune checkpoint…
- Trial name
- NCT06031597
- Testing
- radiotherapy, Platinum-Based Drug, Immunotherapy
- Volunteers
- 105 people
- Sponsor
- Zhejiang Cancer Hospital
Langerhans Cell Histiocytosis (LCH)
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder in children, caused by excessive proliferation and accumulation of Langerhans cells (a type of immune cell) in various body tissues.
- Trial name
- NCT07431060
- Testing
- Prednisone, Vincristine, Mercaptopurine
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- West China Second University Hospital
Interstitial Lung Diseases (ILD)
TBLC vs NIVATS in Interstitial Lung Disease
Patients with suspected interstitial lung disease (ILD) may require a lung biopsy when clinical and imaging findings are inconclusive.
- Trial name
- NCT07910448
- Testing
- NIVATS biopsy, TBLC biopsy
- Where
- Portugal
- Volunteers
- 74 people
- Sponsor
- Rita Alexandra Afonso da Costa
Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
Correlation Between Circulating Fibroblast Activation Protein (FAP) and Fibrosis in Two Diseases (Rheumatoid Arthritis and Systemic Sclerosis)
This study aims to measure a blood protein called fibroblast activation protein (FAP), which is linked to tissue scarring and inflammation.
- Trial name
- FAP (NCT07393217)
- Where
- Egypt
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Sohag University
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a type of scarring (fibrotic) lung disease. Reduced exercise capacity is a key symptom experienced by patients.
- Trial name
- BEET-IPF (NCT06488638)
- Testing
- nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) and the 3 Minutes Sit-to-stand Test
This study is designed to evaluate the reproductibility and the performance of the 3 minutes sit-to-stand test in patients with idiopathic pulmonary fibrosis.
- Trial name
- ST2-IPF (NCT03268915)
- Testing
- 3 minutes sit-to-stand test
- Where
- 2 sites in France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Grenoble
Chronic and Accelerated Silicosis
Safety of Stem Cells Intrabronchial Instillation for Silicosis
The aim of this study was to analyze the safety, pulmonary function, and quality of life data of patients with silicosis treated with intrabronchial instillation of bone marrow derived mononuclear cells (BMDMC, 2x107) through…
- Trial name
- SilicStemCell (NCT01239862)
- Testing
- Autologous cell transplantation
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Interstitial Lung Disease
Correlation Between PaO2/FiO2 and Lung Ultrasound Score in the Intensive Care Unit
The goal of this physiological interventional prospective study is to evaluate the improvement of the previously demonstrated correlation between PaO2/ FiO2 and Lung Ultrasound score (LUSS) in patients admitted in the ICU with an…
- Trial name
- O2LUSSU (NCT05631756)
- Testing
- Lung Ultrasound
- Where
- 2 sites in Belgium
- Volunteers
- 86 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Pulmonary Sarcoidosis
Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).
The aim of the study is determining the non-inferiority in the overall success rate and the safety for a combination therapy with hydroxychloroquine plus low dose glucocorticoids compared to that for high dose glucocorticoids at…
- Trial name
- HySSAS (NCT02200146)
- Testing
- Prednisone, Hydroxychloroquine + Prednisone
- Where
- Italy
- Volunteers
- 94 people
- Sponsor
- University of Milano Bicocca
Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe.
- Conditions
- Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
- Trial name
- NCT07201922
- Testing
- Nerandomilast
- Where
- 55 sites in United States, Argentina and 11 more
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, IPF
Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF
This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo.
- Trial name
- NCT06331624
- Testing
- Tazarotene (GRI-0621)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- GRI Bio Operations, Inc.
Fibrosis Lung, Respiratory Therapy
Automated Oxygen Titration During Walking in Patients With Lung Fibrosis (OXYWILD)
Fibrotic lung disease is a group of severe scarring lung diseases with a dismal prognosis, often leading to respiratory failure and need for oxygen treatment.
- Trial name
- OXYWILD (NCT06465654)
- Testing
- Automated variable dose oxygen treatment, Fixed dose oxygen treatment
- Where
- Denmark
- Volunteers
- 29 people
- Sponsor
- Janne Hastrup Jensen
Idiopathic Pulmonary Fibrosis
Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
A Phase 2a, multicenter, 4-part, randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and PK of once-daily treatment with PLN-74809 in participants with idiopathic pulmonary…
- Trial name
- NCT04396756
- Testing
- PLN-74809
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 120 people
- Sponsor
- Pliant Therapeutics, Inc.
Pulmonary Fibrosis, Rheumatoid Arthritis
Specimen Collection for Individuals With Lung Disease Associated With Rheumatoid Arthritis
Pulmonary fibrosis (PF) is a condition in which the lungs of a patient become scarred and fibrous. It has been known to occur in as many as 40% of patients diagnosed with rheumatoid arthritis (RA).
- Trial name
- NCT00001884
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Systemic Sclerosis
MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis
To define a target value of AUC MPA to improve the modified Rodnan score and / or respiratory impairment (DLCO or FVC) at one year in patients receiving MMF for the treatment of diffuse cutaneous or interstitial lung damage of…
- Trial name
- SCLERAMAC (NCT04244916)
- Testing
- AUC of MPA measure
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Small Cell Lung Cancer
Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD
This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution.
- Trial name
- LOOP (NCT06192004)
- Testing
- None (Observational Study)
- Where
- 23 sites in United States
- Volunteers
- 83 people
- Sponsor
- AstraZeneca
Systemic Sclerosis
Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
PSSc-001 (LOTUSS) This study is a Phase 2, multinational, open-label, randomized, parallel-group, safety and tolerability study of pirfenidone in participants with systemic sclerosis-related interstitial lung disease (SSc-ILD).
- Trial name
- LOTUSS (NCT01933334)
- Testing
- Pirfenidone
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 63 people
- Sponsor
- Genentech, Inc.
Interstitial Lung Disease, Scleroderma
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
Patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary hypertension (PH) do not fit well into the current classification system and treatments for pulmonary hypertension.
- Conditions
- Interstitial Lung Disease, Scleroderma, Pulmonary Hypertension
- Trial name
- CRUSADE (NCT03726398)
- Testing
- Opsumit 10 Mg Tablet
- Where
- United States
- Sponsor
- Franz Rischard, DO
Idiopathic Pulmonary Fibrosis
Daoyin Technique for Improving Exercise Endurance in IPF
This study is based on the previously constructed digital rehabilitation management platform, scientifically evaluating the clinical efficacy of guided technology in improving IPF exercise endurance, and forming high-quality…
- Trial name
- NCT07019714
- Testing
- Daoyin Technique, Routine Comprehensive Training
- Where
- 3 sites in China
- Volunteers
- 236 people
- Sponsor
- Affiliated Hospital of Liaoning University of Traditional Chinese Medicine